Viewing Study NCT02751918


Ignite Creation Date: 2025-12-25 @ 5:02 AM
Ignite Modification Date: 2026-01-03 @ 11:05 PM
Study NCT ID: NCT02751918
Status: COMPLETED
Last Update Posted: 2019-11-22
First Post: 2016-04-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Sponsor: Bayer
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module